Aging, Amyloidosis and levels of Transthyretin Oxidative Carbonylation
Aging, Amyloidosis and levels of Transthyretin Oxidative Carbonylation
批准号:
9144297
负责人:
Natalia Reixach
金额:
$9.63万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-09-30 至 2016-10-01
关键词:
AddressAgeAgingAging-Related ProcessAlzheimer&aposs DiseaseAmyloidAmyloid FibrilsAmyloidosisAntioxidantsBiologicalBiopsyCardiacCerebrospinal FluidCessation of lifeClinical TrialsDataDepositionDevelopmentDiagnosisDiseaseEnzyme-Linked Immunosorbent AssayExperimental DesignsFoundationsFunctional disorderGeneticGoalsHealthHistologicHumanIn VitroIndividualMethodsModificationNeurodegenerative DisordersOnset of illnessOrganParkinson DiseasePatientsPlasmaPlayPost-Translational Protein ProcessingPrealbuminProteinsProtocols documentationRecombinantsReportingRisk FactorsRoleSamplingSiteStructureSyndromeTestingTherapeutic InterventionTissuesTransgenic AnimalsTransgenic MiceWestern BlottingWorkage relatedagedamyloid formationantioxidant therapybasedisease diagnosisextracellularin vivomouse modelmutantnovel therapeutic interventionnovel therapeuticsoxidationprematurepreventprotein aggregationprotein misfolding
中文摘要
描述(由申请人提供):转甲状腺素淀粉样变性是一种致命的蛋白质错误折叠疾病,其特征是来自血浆同四聚体蛋白转甲状腺素(TTR)的聚集体和淀粉样原纤维的细胞外沉积。衰老是这些疾病的老年性(野生型)和遗传性(突变型TTR)形式的主要危险因素。事实并非如此
英文摘要
DESCRIPTION (provided by applicant): The transthyretin amyloidoses are fatal protein misfolding disorders characterized by the extracellular deposition of aggregates and amyloid fibrils derived from the plasma homotetrameric protein transthyretin (TTR). Aging is a major risk factor for both the senile (wild-type) and genetic (mutant TTR) forms of these disorders. It is not
known which aspects of the aging process contribute to the onset of the TTR amyloidoses. Protein carbonylation is an oxidative modification common of old age and it is associated with age-related neurodegenerative illnesses such as Alzheimer's and Parkinson's diseases. We previously established in vitro that recombinant carbonylated TTR (car-TTR) is less stable and has higher propensity to aggregate than non-oxidized TTR. We also demonstrated that the only therapy currently under clinical trials based on TTR tetramer stabilization is significantly less efficient for car-TTR than for non-oxidized TTR. The implications of these studies are that if car-TTR levels increase with age, they will promote the onset of the amyloidoses; moreover, tetramer stabilization therapy may not be sufficient to treat these disorders. Although car-TTR has been detected in plasma of healthy individuals, no systematic studies exist with respect to its changing abundance with age or with the presence of TTR amyloidoses. Our working hypotheses are: 1) Car-TTR content in plasma increases with age; 2) Car-TTR content in plasma is higher in TTR amyloid patients than in healthy controls. Our goals are to establish whether an increase in car-TTR in plasma is associated with age and/or with overt TTR amyloidoses. To accomplish these goals we will exploit our already established methods to quantify total TTR in plasma and optimize our working protocols to specifically quantify car-TTR in the same samples. The experimental design includes the following groups: i) Healthy humans aged 20 to 72 years; ii) Patients with TTR amyloidosis and age-matched healthy controls; iii) Healthy young and old transgenic mice over-expressing human wild-type TTR; iv) Transgenic mice over-expressing human wild-type TTR, with and without histologically confirmed TTR deposition. Finding a correlation between car-TTR content with age and/or the positive diagnosis of TTR amyloidosis, together with the already established fact that car-TTR is more prone to aggregation than non-oxidized TTR, will indicate that this type of age-related oxidative modification may play a role in the onset of the TTR aggregation disorders. It will also open a new therapeutic approach to prevent disease onset consisting in anti-oxidant therapy to preclude car-TTR formation. We will formally test the causal hypothesis, i.e. car-TTR formation is involved in the onset of the TTR amyloidoses, and the novel therapeutic strategy in vivo in a forthcoming R01 proposal. Finally, the results of our studies can have direct implications to the understanding of the initiation of other age-related diseases of protein aggregation where the precursor amyloidogenic proteins might be susceptible to the same type of oxidative modifications.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Probing the cellular Mechanisms of Transthyretin Cytotoxicity
-
批准号:8481488
-
项目类别:
-
资助金额:$35.36万
-
财政年份:2010
-
负责人:Natalia Reixach
-
依托单位:
Probing the cellular Mechanisms of Transthyretin Cytotoxicity
-
批准号:8680097
-
项目类别:
-
资助金额:$37.42万
-
财政年份:2010
-
负责人:Natalia Reixach
-
依托单位:
Probing the cellular Mechanisms of Transthyretin Cytotoxicity
-
批准号:8101967
-
项目类别:
-
资助金额:$37.42万
-
财政年份:2010
-
负责人:Natalia Reixach
-
依托单位:
Probing the cellular Mechanisms of Transthyretin Cytotoxicity
-
批准号:8284374
-
项目类别:
-
资助金额:$37.42万
-
财政年份:2010
-
负责人:Natalia Reixach
-
依托单位:
Probing the cellular Mechanisms of Transthyretin Cytotoxicity
-
批准号:7980179
-
项目类别:
-
资助金额:$38.93万
-
财政年份:2010
-
负责人:Natalia Reixach
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: